NEOSTAR Trial: Neoadjuvant Immunotherapy for Operable Lung Cancer

The NEOSTAR trial (NCT03158129) was a phase 2 randomized study of 44 patients with operable non-small cell lung cancer. It compares neoadjuvant nivolumab monotherapy to nivolumab plus ipilimumab, with major pathologic response as the primary endpoint. The dataset, from paperswithcode, includes results on response rates, tumor viability, and immune cell frequencies.

Use Cases

• Modeling major pathologic response based on treatment regimen and immune cell frequencies
• Analyzing associations between gut microbiome species and treatment response
• Comparing pathologic complete response rates between monotherapy and combination immunotherapy

Strengths

• Data originates from a defined phase 2 randomized controlled trial (NEOSTAR, NCT03158129)
• Includes specific response rates: 38% MPR for combination therapy, 22% MPR for monotherapy
• Reports on multiple correlated endpoints: pathologic response, tumor viability, and immune cell frequencies

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download
• Data may reflect bias inherent to a single clinical trial's patient population and protocol
• Last update date is unknown; freshness unverified

Provenance

Source

T Cascone via paperswithcode

Collection Method

Data collected as part of the phase 2 randomized NEOSTAR clinical trial.